July 20, 2017
Daiichi Sankyo and Canadian biotech Zymeworks said on July 19 that they have successfully achieved a research milestone for an immuno-oncology bispecific antibody therapeutic candidate, triggering a payment of US$1 million from the Japanese drug major. The two companies concluded...read more